Murray P G, Swinnen L J, Constandinou C M, Pyle J M, Carr T J, Hardwick J M, Ambinder R F
Johns Hopkins Oncology Center, Baltimore, MD 21231, USA.
Blood. 1996 Jan 15;87(2):706-11.
Posttransplantation lymphoproliferative disease (PTLD) is virtually always associated with Epstein-Barr virus (EBV) infection. BCL-2 and other proteins that confer resistance to apoptosis have been implicated in the pathogenesis of a variety of malignancies including lymphomas. One EBV protein, BHRF1, is a homologue of BCL-2, whereas another, the latency membrane protein 1 (LMP-1), upregulates BCL-2 expression in vitro. In the present study, we used immunohistochemistry to study the expression of these viral and cellular proteins as well as a variety of other EBV-encoded proteins in PTLD. BHRF1 was not detected in any PTLD specimen, whereas BCL-2 was shown in 12 of 17 lesions examined. With one exception, all LMP1-positive cases also expressed BCL-2 and the absence of LMP1 was always associated with a lack of BCL-2 expression. The results do not support a role for the EBV homologue of BCL-2 in PTLD, but they do support a role for viral induction of BCL-2 expression.
移植后淋巴细胞增生性疾病（PTLD）几乎总是与爱泼斯坦-巴尔病毒（EBV）感染相关。BCL-2和其他赋予细胞抗凋亡能力的蛋白质与包括淋巴瘤在内的多种恶性肿瘤的发病机制有关。一种EBV蛋白BHRF1是BCL-2的同源物，而另一种潜伏膜蛋白1（LMP-1）在体外可上调BCL-2的表达。在本研究中，我们使用免疫组织化学方法研究了这些病毒和细胞蛋白以及多种其他EBV编码蛋白在PTLD中的表达情况。在任何PTLD标本中均未检测到BHRF1，而在17个检查的病变中有12个显示有BCL-2表达。除1例例外，所有LMP1阳性病例也表达BCL-2，且LMP1缺失总是与BCL-2表达缺失相关。结果不支持BCL-2的EBV同源物在PTLD中起作用，但支持病毒诱导BCL-2表达起作用。
